Conference Review | Tianmu Biotechnology Participated in the Training for the Construction of the Fourth Phase of the Bio Manufacturing Pilot Platform in 2025

From May 26th to 27th, 2025, by Dr. FangArterial networkThe training on the ideas and plans for the construction of the fourth phase of the biomanufacturing pilot platform in 2025, jointly organized, has successfully concluded in Suzhou. This conference brought together more than 80 industry elites from the government, industrial parks, research institutes, and leading companies in the field of biomanufacturing to conduct in-depth discussions on technological breakthroughs, equipment innovation, and industrial applications in the construction of pilot platforms.

During the conference, experts from East China University of Science and Technology and Tianjin Institute of Chinese Academy of Sciences shared their practical experience in biological process amplification, equipment selection, platform operation, and other dimensions. Tianmu Biotechnology as a high-throughput screening equipmentexcellentThe enterprise was invited to attend and give a keynote speech on "System Innovation, AI Empowerment, Development and Industrialization of High throughput Screening Equipment", providing breakthrough ideas for industry pain points.

At the conference, Dr. Zhang, the R&D Director of Tianmu Biotechnology, introduced the core technologies and equipment of Tianmu Biotechnology in high-throughput screening systems, including plasma mutagenesis breeding equipment, single-cell micro droplet culture and screening equipment, micro droplet continuous passage culture evolution equipment, biochemical online detection equipment, and more than 20 other products. He shared the following core experiences on how to empower the construction of pilot platforms:

• Chassis cell modification: Based on atmospheric pressure room temperature plasma technology (ARTP) mutagenesis library construction, 600000 to 1 million strains can be induced within minutes, which is safe, easy and controllable, creating efficient strains from the source.

• High throughput cell screening: based on dropletsmicrofluidic technologyRealize high-throughput strain screening and significantly increase the screening scale,10^6The screening cycle of the strain library can be shortened to 24 hours,The dosage of detection reagents has decreased by 99.99% from mL level (shake flask) to pL level (microdroplets), based on system innovation to screen target strains, greatly reducing time and material costs.

• Fully automatic adaptive evolution: Using microfluidic droplet generation technology, a closed-loop directed evolution cycle of 'generation stress detection passage' is constructed, greatly reducing labor and time costs. Single consumables can be used for 30 days/100 passages, greatly reducing shaking bottle/deep hole plate usage/pipette tipThe usage amount.

• Biological process evaluation:Transform the fragmented 'environmental control process monitoring parameter adjustment' process in traditional fermentation technology into an intelligent linkage whole, and build a fully automatic ingredient analyzer (ABI), fully automatic sampler (ASI), and multi parameter biochemical sample automatic processing analyzer（MBP）A series of equipment including Tmax Bio series bioreactors, BODS (Biological Cultivation Process Online Detection System), FAP (Flexible Automated Detection Platform), etc.

In addition, Dr. Zhang stated that Tianmu Biotechnology will simultaneously undertake the public service functions of the pilot platform and provide external technical services, including new technology, new products, new model application construction experiments, application verification, etc. Tianmu Biotechnology has provided over 200 technical services annually, which provides valuable insights and experience for promoting technological iteration and upgrading, promoting innovative product applications, and enhancing value.

Tianmu Biotechnology Exhibition Stand

Looking ahead to the future

This conference not only provided a pilot construction plan for the industry to learn from, but also promoted the deep connection between industry, academia, research and application through on-site visits to the Weikang probiotic factory and case analysis of enterprises.

In the future, Tianmu Biotechnology will continue to deeply cultivate the field of AI+biomanufacturing equipment, jointly build an open ecosystem with industry partners, promote the transformation of pilot platforms from "experience driven" to "data intelligent driven", and accelerate the last mile leap of biomanufacturing technology from laboratory to industrialization!